ICS/LABA Adherence and COPD Exacerbation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation

NCT01431911

Pulmonary Disease, Chronic Obstructive

COMPLETED

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

NCT04072887

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

NCT01757015

Chronic Obstructive Pulmonary Disease

WITHDRAWN PHASE3

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018

Chronic Obstructive Pulmonary Disease, COPD

COMPLETED PHASE2

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

NCT01443845

COPD COPD Exacerbation Lung Diseases +4 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This retrospective, observational study will assess the effectiveness of ICS/LABA combination therapies among COPD patients new to the ICS/LABA combination therapies in the US, comparing those who are adherent to the index medication and those who are non-adherent. Adherence will be measured using the proportion of days covered with the index medication. Medical and pharmacy claims data will be used as the data source.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICS/LABA Patients

ICS/LABA Patients following standard of care

Non-Interventional Study

Intervention Type OTHER

Non-Interventional Study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Interventional Study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least one prescription fill for ICS/LABA combination during identification period.
* COPD diagnosis
* 40 years or older at index date
* \> or = 12 months of continuous health plan enrollment prior to and following index date
* 1 or more prescription for SABA, SAMA or SABA/SAMA during the pre-index period.

Exclusion Criteria

* Patients with prescription claim for ICS/LABA combination therapy during the 12 month pre-index period
* Patients receiving oral corticosteroid medication for more than 180 days during the 12 month pre-index period
* Patients with cancer diagnosis in 12 month pre-index period

Minimum Eligible Age

40 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No